CN111108119B - 新型抗CD3ε抗体 - Google Patents

新型抗CD3ε抗体 Download PDF

Info

Publication number
CN111108119B
CN111108119B CN201880056557.3A CN201880056557A CN111108119B CN 111108119 B CN111108119 B CN 111108119B CN 201880056557 A CN201880056557 A CN 201880056557A CN 111108119 B CN111108119 B CN 111108119B
Authority
CN
China
Prior art keywords
seq
variable region
chain variable
antigen
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880056557.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN111108119A (zh
Inventor
李竞
梅芹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuxi Biologics Shanghai Co Ltd
Original Assignee
Wuxi Biologics Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Biologics Shanghai Co Ltd filed Critical Wuxi Biologics Shanghai Co Ltd
Priority to CN202211326811.1A priority Critical patent/CN115991777A/zh
Publication of CN111108119A publication Critical patent/CN111108119A/zh
Application granted granted Critical
Publication of CN111108119B publication Critical patent/CN111108119B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880056557.3A 2017-09-21 2018-09-20 新型抗CD3ε抗体 Active CN111108119B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211326811.1A CN115991777A (zh) 2017-09-21 2018-09-20 新型抗CD3ε抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2017/102622 2017-09-21
CN2017102622 2017-09-21
PCT/CN2018/106618 WO2019057099A1 (en) 2017-09-21 2018-09-20 NOVEL ANTI-CD3EPSILON ANTIBODIES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211326811.1A Division CN115991777A (zh) 2017-09-21 2018-09-20 新型抗CD3ε抗体

Publications (2)

Publication Number Publication Date
CN111108119A CN111108119A (zh) 2020-05-05
CN111108119B true CN111108119B (zh) 2022-11-15

Family

ID=65811028

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880056557.3A Active CN111108119B (zh) 2017-09-21 2018-09-20 新型抗CD3ε抗体
CN202211326811.1A Pending CN115991777A (zh) 2017-09-21 2018-09-20 新型抗CD3ε抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202211326811.1A Pending CN115991777A (zh) 2017-09-21 2018-09-20 新型抗CD3ε抗体

Country Status (18)

Country Link
US (2) US11440962B2 (enExample)
EP (1) EP3684806A4 (enExample)
JP (2) JP7305624B2 (enExample)
KR (2) KR102785140B1 (enExample)
CN (2) CN111108119B (enExample)
AU (2) AU2018336519B2 (enExample)
BR (1) BR112020004992A2 (enExample)
CA (1) CA3074130A1 (enExample)
EA (1) EA202090800A1 (enExample)
IL (1) IL273393A (enExample)
MX (1) MX2020003087A (enExample)
MY (1) MY199530A (enExample)
PH (1) PH12020550078A1 (enExample)
SA (2) SA523440043B1 (enExample)
SG (1) SG11202001358RA (enExample)
TW (2) TWI820041B (enExample)
WO (1) WO2019057099A1 (enExample)
ZA (1) ZA202001314B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL273424B2 (en) 2017-09-22 2024-09-01 Wuxi Biologics Ireland Ltd Novel bispecific cd3/cd19 polypeptide complexes
IL273217B2 (en) 2017-09-22 2025-04-01 Wuxi Biologics Ireland Ltd Novel bispecific polypeptide complexes
EP3973000A4 (en) * 2019-06-07 2023-09-06 Adimab, LLC HIGH AFFINITY ANTI-CD3 ANTIBODIES AND METHOD FOR THE PRODUCTION AND USE THEREOF
US20230067182A1 (en) * 2019-11-29 2023-03-02 Boe Technology Group Co., Ltd. Data Processing Device and Method, and Computer Readable Storage Medium
JP7765397B2 (ja) 2020-03-12 2025-11-06 イミューン－オーエヌシー セラピューティクス，インコーポレーテッド 新規抗ｌｉｌｒｂ４抗体および派生産物
JP2023528350A (ja) 2020-05-27 2023-07-04 ヤンセン バイオテツク，インコーポレーテツド Ｃｄ３抗原結合ドメインを含むタンパク質及びその使用
WO2022022464A1 (zh) * 2020-07-27 2022-02-03 正大天晴药业集团股份有限公司 新型双特异性抗cd3/cd20多肽复合物配制剂
US11795224B2 (en) * 2021-03-24 2023-10-24 China Medical University Hospital Anti-T-cell nanobody and nucleic acid encoding sequence thereof, and uses of the same
US12258406B2 (en) 2021-03-24 2025-03-25 Twist Bioscience Corporation Antibodies that bind CD3 Epsilon
CN115536740A (zh) * 2021-06-30 2022-12-30 苏州方德门达新药开发有限公司 介导细胞内有效滞留cd3的空间构象表位及其应用
CN115558023A (zh) * 2021-07-02 2023-01-03 安源医药科技（上海）有限公司 抗cd3抗体及其用途
CN118922442A (zh) * 2022-03-14 2024-11-08 成都盛世君联生物技术有限公司 一种抗cd3抗体及其制备方法和用途
CN115286715B (zh) * 2022-05-18 2023-05-23 上海百英生物科技股份有限公司 一种抗cd3的纳米抗体或其抗原结合部分及其制备方法
AU2023367039A1 (en) * 2022-10-25 2025-05-15 Ablexis, Llc Anti-cd3 antibodies
EP4623007A1 (en) 2022-11-24 2025-10-01 WuXi Biologics Ireland Limited Psma antibodies and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142000A1 (en) * 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
CN1169953C (zh) * 1999-11-30 2004-10-06 中国医学科学院中国协和医科大学血液学研究所血液病医院 抗cd3单克隆抗体重链和轻链可变区基因及其应用
UA94211C2 (ru) * 2004-06-03 2011-04-26 Новиммюн С.А. Выделенное полностью человеческое моноклональное cd3 антитело
DK1940881T3 (en) * 2005-10-11 2017-02-20 Amgen Res Munich Gmbh COMPOSITIONS WITH ARTICLE CROSS-SPECIFIC ANTIBODIES AND APPLICATIONS THEREOF
CA2682626A1 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
FI2155783T4 (fi) * 2007-04-03 2022-12-15 Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni
WO2010037836A2 (en) 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific psmaxcd3 bispecific single chain antibody
WO2011109588A1 (en) 2010-03-03 2011-09-09 Health Research Inc. Novel cd3 epsilon immunogens and antibodies
CN104098698B (zh) * 2013-04-08 2019-04-05 中国人民解放军第二军医大学 一种抗cd3抗体及其制法和应用
SG11201509361TA (en) * 2013-05-28 2015-12-30 Numab Ag Novel antibodies
CN112390883A (zh) 2013-12-17 2021-02-23 基因泰克公司 抗cd3抗体及使用方法
AU2015266077A1 (en) 2014-05-28 2016-09-29 F. Hoffmann-La Roche Ag Antibodies binding to human and cynomolgus CD3 epsilon
AU2015329965A1 (en) * 2014-10-09 2017-04-27 Engmab Sàrl Bispecific antibodies against CD3epsilon and ROR1
TN2018000324A1 (en) * 2015-01-23 2020-01-16 Sanofi Sa ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123

Also Published As

Publication number Publication date
TWI820041B (zh) 2023-11-01
CN111108119A (zh) 2020-05-05
KR20250046337A (ko) 2025-04-02
TW202428617A (zh) 2024-07-16
MY199530A (en) 2023-11-03
NZ762170A (en) 2023-10-27
MX2020003087A (es) 2020-08-17
TWI879275B (zh) 2025-04-01
US20200299384A1 (en) 2020-09-24
BR112020004992A2 (pt) 2020-10-06
US11440962B2 (en) 2022-09-13
EA202090800A1 (ru) 2020-08-11
JP7737193B2 (ja) 2025-09-10
TW201922787A (zh) 2019-06-16
SA523440043B1 (ar) 2024-02-08
ZA202001314B (en) 2021-08-25
WO2019057099A1 (en) 2019-03-28
CN115991777A (zh) 2023-04-21
KR20200055052A (ko) 2020-05-20
US20230192850A1 (en) 2023-06-22
SG11202001358RA (en) 2020-03-30
AU2025201457A1 (en) 2025-03-20
PH12020550078A1 (en) 2022-07-18
AU2018336519A1 (en) 2020-03-05
JP7305624B2 (ja) 2023-07-10
JP2020534830A (ja) 2020-12-03
EP3684806A4 (en) 2021-09-22
EP3684806A1 (en) 2020-07-29
SA520411577B1 (ar) 2024-02-08
US12485298B2 (en) 2025-12-02
JP2023126851A (ja) 2023-09-12
AU2018336519B2 (en) 2024-12-19
KR102785140B1 (ko) 2025-03-25
CA3074130A1 (en) 2019-03-28
IL273393A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
CN111108119B (zh) 新型抗CD3ε抗体
CN112218892B (zh) 新型抗ctla-4抗体多肽
WO2019179391A1 (en) Novel bispecific pd-1/ctla-4 antibody molecules
US20240052052A1 (en) Novel anti-cd24 antibodies
CN109535253B (zh) 新型抗cd19抗体
JP7438180B2 (ja) 新規抗ｌａｇ－３抗体ポリペプチド
WO2020192709A1 (en) Novel bispecific polypeptide complexes
US20210115138A1 (en) Novel bispecific pd-1/lag-3 antibody molecules
CN110305216B (zh) 新型抗tim-3抗体
US12486325B2 (en) Anti-CD3epsilon antibodies
WO2019179420A1 (en) Novel anti-tim-3 antibodies
EA042856B1 (ru) Новые анти-cd3-эпсилон антитела
NZ762170B2 (en) Novel anti-cd3epsilon antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant